Bell v. JPMorgan Chase Bank, N.A.
- Paul Gardephe
- 1:20-cv-02468
- U.S. District Court · Southern District of New York
- 5
In Bell v. JPMorgan Chase, Judge Gardephe granted Chase’s motion in limine to exclude prognosis testimony unless Bell timely supplements the expert submission.
The ruling directly affected Rachel Bell’s ability to present Dr. Nirmal Tejwani’s opinions about possible future hip arthritis and hip replacement, and addressed JPMorgan Chase Bank, N.A.’s motion to exclude that testimony. The opinion does not state how the ruling affected Jones Lang Lasalle Americas, Inc.
What happened
In Bell v. JPMorgan Chase Bank, N.A., Rachel Bell sought to present testimony from Dr. Nirmal Tejwani about possible long-term arthritis and a future hip replacement after her hip injury.
JPMorgan Chase Bank, N.A. argued that the opinions were speculative because they used terms such as “may” and “potentially.” Bell argued that medical experts can describe possible or likely future outcomes and that Chase could challenge the opinions through cross-examination.
Judge Paul G. Gardephe ruled that the record did not show the facts, data, methods, or reasoning supporting Dr. Tejwani’s prognosis opinions. The court stated that Chase’s motion in limine would be granted unless Bell filed a supplemental submission satisfying the expert-evidence requirements by April 10, 2023.
The detailed version
- Bell v. JPMorgan Chase Bank, N.A. · No. 1:20-cv-02468
- Paul Gardephe
- Apr. 4, 2023
Background
Rachel Bell alleged that she tripped and fell outside a JPMorgan Chase branch and suffered serious injuries, including a fractured hip. Trial was scheduled for April 17, 2023. Chase asked the court to prevent Bell from presenting two opinions by Dr. Nirmal Tejwani, her treating physician and designated expert: that her injury was likely to cause hip arthritis over the long term and that she might eventually need a hip replacement if her pain worsened.
Dr. Tejwani’s report used the phrases “may result” and “may potentially need.” During his deposition, he testified that doctors are concerned about hip arthritis after injuries of this type, but he did not identify when arthritis might develop. The opinion states that neither his report nor his deposition explained the facts or data he considered, the methods he used, or why Bell’s particular injury supported those opinions. The opinion also states that he did not discuss the possibility of a hip replacement during his deposition.
Parties’ Positions
Chase argued that the prognosis testimony was speculative and could confuse the jury because it was not stated to a reasonable degree of medical certainty. Bell responded that medical experts cannot know the future with certainty and may testify about outcomes that are possible, likely, or foreseeable. She also argued that Chase could address the strength of the opinions through cross-examination.
Court’s Analysis
Federal Rule of Evidence 702 permits qualified experts to testify when their specialized knowledge will help the jury, their testimony is based on sufficient facts or data, their principles and methods are reliable, and they reliably applied those principles and methods to the case. The court explained that when a treating doctor offers opinions going beyond knowledge gained in the treating role, the party offering the testimony must establish that it meets this standard. The court also considered the reliability principles associated with Daubert v. Merrell Dow Pharmaceuticals, Inc.
The court concluded that Bell had not shown an adequate basis for Dr. Tejwani’s long-term prognosis testimony under Rule 702 and Daubert. His report did not identify the supporting facts or data, the principles and methods used, or how those methods were applied to Bell’s circumstances. His deposition testimony likewise did not explain why he was concerned about arthritis in cases like Bell’s or why he believed Bell might later develop arthritis. The court also noted the lack of deposition testimony addressing a possible hip replacement.
Ruling
Judge Paul G. Gardephe stated that Chase’s motion in limine to exclude Dr. Tejwani’s testimony about Bell’s long-term risk of arthritis and hip replacement “will be granted absent a supplementary submission” from Bell that meets Rule 702 and Daubert. The court gave Bell until April 10, 2023, to file that submission. The opinion does not state whether Bell filed one or what ruling followed.
Read the full 5-page opinion on CourtListener, the free public archive maintained by the Free Law Project.